Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Interference of bile salt transport is one of the underlying mechanisms for drug-induced liver injury (DILI). We developed a novel bile salt transport activity assay involving in situ biosynthesis of bile salts from their precursors in primary human, monkey, dog, rat, and mouse hepatocytes in suspension as well as LC-MS/MS determination of extracellular bile salts transported out of hepatocytes. Glycine- and taurine-conjugated bile acids were rapidly formed in hepatocytes and effectively transported into the extracellular medium. The bile salt formation and transport activities were time– and bile-acid-concentration–dependent in primary human hepatocytes. The transport activity was inhibited by the bile salt export pump (BSEP) inhibitors ketoconazole, saquinavir, cyclosporine, and troglitazone. The assay was used to test 86 drugs for their potential to inhibit bile salt transport activity in human hepatocytes, which included 35 drugs associated with severe DILI (sDILI) and 51 with non-severe DILI (non-sDILI). Approximately 60% of the sDILI drugs showed potent inhibition (with IC50 values <50 μM), but only about 20% of the non-sDILI drugs showed this strength of inhibition in primary human hepatocytes and these drugs are associated only with cholestatic and mixed hepatocellular cholestatic (mixed) injuries. The sDILI drugs, which did not show substantial inhibition of bile salt transport activity, are likely to be associated with immune-mediated liver injury. Twenty-four drugs were also tested in monkey, dog, rat and mouse hepatocytes. Species differences in potency were observed with mouse being less sensitive than other species to inhibition of bile salt transport. In summary, a novel assay has been developed using hepatocytes in suspension from human and animal species that can be used to assess the potential for drugs and/or drug-derived metabolites to inhibit bile salt transport and/or formation activity. Drugs causing sDILI, except those by immune-mediated mechanism, are highly associated with potent inhibition of bile salt transport.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“Species differences in DILI are well-recognized [19,20].”
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
FDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
Self-citationDawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft176 · Cited by 243 · cited 5×
“However, this membrane vesicle assay lacks the capacity to assess the role of in situ drug metabolism, and therefore could generate false negative results if a metabolite causes inhibition or false positive results if a drug is rapidly metabolized to inactive metabolites, when compared with clinical outcomes [3,8,9].”
BackgroundMethodResultInfluentialSelf-citationAleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., & Will, Y. (2014) · Hepatology · doi:10.1002/hep.27206 · Cited by 215
Boyer, J. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00519.x · Cited by 124 · cited 1×
“Vanishing bile duct syndrome may involve interference of other molecular targets such as multidrug resistant protein 3 (MDR3) [4], which is responsible for the biliary secretion of phosphatidylcholines [36,37].”
BackgroundTamaki, C., Nagayama, T., Hashiba, M., Fujiyoshi, M., Hizue, M., Kodaira, H., Nishida, M., Suzuki, K., Takashima, Y., Ogino, Y., et al. (2013) · The Journal of Toxicological Sciences · doi:10.2131/jts.38.581 · Cited by 79
Cited by
Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01256 · Cited by 61
Self-citationGill, M. W., Murphy, B. J., Cheng, P. T. W., Sivaraman, L., Davis, M., & Lehman-McKeeman, L. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115885 · Cited by 41
Gupta, K., Ng, I. C., Balachander, G. M., Nguyen, B. P., Tucker-Kellogg, L., Low, B. C., & Yu, H. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120283 · Cited by 23
“We treated hepatocytes with 20 μ M GB (MRP2 inhibitor [36]) and 12 μ M KTZ (BSEP inhibitor [37]).”
Andújar-Vera, F., Alés-Palmer, M. L., Muñoz-de-Rueda, P., Iglesias-Baena, I., & Ocete-Hita, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713562 · Cited by 10
Metadata
- Authors
- Zhang, J., He, K., Cai, L., Chen, Y.-C., Yang, Y., Shi, Q., Woolf, T. F., Ge, W., Guo, L., Borlak, J., & Tong, W.
- Venue
- Chemico-Biological Interactions
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 255
- Pages
- 45-54
- ISSN
- 0009-2797 (ISSN-L)
- OpenAlex
- W2302952418
- Cited by
- 44
- References
- 8
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse. https://app.cochat.ai/papers/10.1016/j.cbi.2016.03.019
- The paper
- Zhang, J., He, K., Cai, L., Chen, Y.-C., Yang, Y., Shi, Q., Woolf, T. F., Ge, W., Guo, L., Borlak, J., & Tong, W. (2016). Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse. Chemico-Biological Interactions. https://doi.org/10.1016/j.cbi.2016.03.019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.